AD/PD 2024 | Will blood-based biomarkers replace PET for trial recruitment?

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, briefly comments on the use of novel blood-based biomarkers for clinical trial enrolment screening. With emerging data emphasizing the relevance of tau levels for anti-amyloid therapy efficacy, markers capable to categorizing patients into low, intermediate, or high phosphorylated tau levels are of increasing importance. Currently, tau-PET can provide this information but blood-based biomarkers specific for tau pathology are yet to be validated. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.